Drug class in one race
BCMA drugs for Multiple Myeloma
33 tracked BCMA drugs in the Multiple Myeloma race. The class explanation lives on the BCMA page; the full indication pipeline across every mechanism is on the Multiple Myeloma page.
3 approved / phase 42 Phase 32 Phase 210 Phase 1/214 Phase 12 preclinical / unstaged
Head-to-head evidence: ALLO-715 vs AZD4045 · ALLO-715 vs Anitocabtagene autoleucel · ALLO-715 vs BCMA CAR-NK (Hrain) · ALLO-715 vs BCMA CAR-NK (Shenzhen Pregene Biopharma) · ALLO-715 vs BCMA-CART (Bioray Laboratories) · ALLO-715 vs BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech)